Medication Storage and Labeling Deficiencies
Summary
Medications and biologicals were not stored in accordance with manufacturer requirements and the facility’s Medication Storage in the Facility policy. In the Station 1 medication room refrigerator, surveyors found the temperature at 32.9 F, which was below the required 36 F to 46 F range. Stored in that refrigerator were multiple medications requiring refrigeration, including an unopened emergency medication kit containing Novolin R, Humalog Kwik Pen, and lorazepam, as well as acetaminophen suppositories, Humulin R vials, Novolin R vials, Rhopressa, latanoprost, Vyzulta, Lantus Solostar pens, insulin lispro, and Trulicity. RN 2 stated the refrigerator should have been maintained between 36 F and 46 F and that the out-of-range temperature could affect medication stability and effectiveness. The refrigerator temperature log also did not show a documented temperature reading for one of the scheduled checks. RN 2 stated the temperature had been documented at 12:00 AM but not at 12:00 PM. During interview, the DON stated the facility replaced the medications that were outside the required temperature range and ordered replacements from the pharmacy. In Station 1 Medication Cart 1B, Resident 155’s unopened prefilled Lantus Solostar pen was found without an open date and was not stored in a refrigerator. The resident had a diagnosis of Type 2 DM, and the order summary showed Lantus Solostar 30 units subcutaneously at bedtime. LVN 5 stated the pen had likely been delivered the day before, but it had not been dated or placed in the refrigerator. The DON stated that if insulin was removed from refrigeration and stored in the cart, it should be labeled with an open date. Also in Station 1 Medication Cart 1B, Resident 54’s opened foil pack containing budesonide inhalation suspension had no open date. The outside box showed a date, but the foil envelope had been opened and the ampules were required to be used within 2 weeks once opened. Resident 54 had diagnoses including COPD with acute exacerbation, acute respiratory failure with hypercapnia, and unspecified asthma with acute exacerbation. LVN 5 stated she was not sure why there was no open date on the foil pack, and the DON stated it was important to follow the manufacturer requirements for budesonide inhalation suspension because the medication could be administered beyond the manufacturer recommendations if not handled properly.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release October 8, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.